Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts).

e20503Background: Since the 1st epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) was launched in Japan, the survival periods of EGFR mutation positive (EGFR m+) advanced/recurrent NSCLC pts have been getting longer. However, clinical factors contributing to the longer survival remains unclear. We investigated the OS, and potential prognostic factors of EGFRm+ NSCLC pts in the real-world clinical practice. Methods: This is a multi-center, observational, retrospective study. NSCLC pts who started first-line treatment from 1/1/2008 to 31/12/2012 were enrolled. Eligible pts were diagnosed with EGFRm+ advanced/recurrent NSCLC by tissue or cytology samples. The primary objective was OS. The secondary objectives were to determine prognostic factors and treatment patterns. We also conducted “Dynamic Treatment Regimen Analysis (DTRA)” to explore the effects of treatment sequence on OS. Results: One thousand six hundred sixty NSCLCpts were enrolled from 17 hospitals in Japan: 64.8% of female, m...